Weekly funding opportunities

[med-Research]

Innovation Award: COVID-19 and Health Equity (U01) Clinical Trials Optional<https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-22-003.html>
The purpose of this funding opportunity announcement (FOA) is to fund innovative research that will strengthen and advance COVID-19 health equity research. The following studies are encouraged under this FOA.

  *   Proposals that advance diversity in COVID-19/COVID-19 variant clinical trials including efforts that (a) identify barriers to enrollment for underrepresented populations (e.g. racial, ethnic minorities), (b) advance evidence for racial and ethnic clinical trial data, (c) employ innovative strategies/trainings/education methods to increase enrollment for underrepresented populations in clinical trials (e.g. racial, ethnic minorities), and/or (d) improve communication strategies and informed messages for underrepresented populations (e.g. racial, ethnic minorities).
  *   Proposals that advance equity in COVID-19 data including efforts that (a) increase evidence to support evaluation of outcomes of FDA-regulated products by demographic data including, but not limited to, ethnicity, race, age, and geography, and/or (b) leverage big data, novel data sources and artificial intelligence/machine learning options to contribute to informing the continued evaluation of the safety and efficacy of FDA-approved products (therapeutics, diagnostics, and vaccines) or products subject to EUAs/EUA expansion.
  *   Proposals that increase understanding of diverse voices affected by COVID-19, including efforts that (a) support research to leverage novel data sources to understand diverse patient preferences and unmet needs, and/or (b) support expansion of culturally and linguistically tailored education (e.g., patient, healthcare providers).
Due November 29, 2021. Med-RA deadline to receive draft documents: November 15 (due to Thanksgiving holiday).

Modern Equipment for Shared-use Biomedical Research Facilities: Advancing Research-Related Operations (R24 Clinical Trials Not Allowed)<https://grants.nih.gov/grants/guide/pa-files/PAR-21-326.html>
This Funding Opportunity Announcement (FOA) invites qualified academic or research institutions to apply for support to purchase and install advanced equipment to enhance and modernize research-supporting operations of biomedical research facilities. Targeted are core facilities, animal research facilities, and other research spaces that are used on a shared basis. The goal of this FOA is to strengthen research-auxiliary activities of biomedical research facilities and to enhance the efficacy of their operation. To ensure proper installation and functioning of the equipment, minor alteration and renovation (A&R) efforts can be included as a small component of the budget.
Due December 1, 2021. Med-RA deadline to receive draft documents: November 15 (due to Thanksgiving holiday).

HEAL Initiative: Advancing Health Equity in Pain Management (R61 / R33 Clinical Trial Required)<https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-22-002.html>
The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications to accelerate development, testing and implementation of evidence-based interventions—that are culturally and linguistically appropriate for NIH-designated populations that experience health disparities (HDPs) in the United States—to mitigate disparities in provision of care and treatment decisions, reduce susceptibility to chronic pain and improve patient outcomes. Expected outcomes of this initiative include evidence-based interventions that mitigate: 1) the effects of bias, stigma and discrimination at multiple levels, and/or 2) socioeconomic, environmental and other barriers to quality pain assessment, treatment and management. Studies that address multiple socioecological domains and levels of influence (e.g. organizational/institutional, community/neighborhood, societal) to advance health equity and mitigate health disparities in pain management are of higher priority. Studies must address research topics within the mission and research interests of participating NIH Institutes and Centers.
Due December 9, 2021. Med-RA deadline to receive draft documents: November 29.

Interventions for Stigma Reduction to Improve HIV/AIDS Prevention, Treatment and Care in Low- and Middle- Income Countries (R01 – Clinical Trial Optional)<https://grants.nih.gov/grants/guide/pa-files/PAR-21-344.html>
The purpose of this FOA is to solicit Research Project Grant (R01) applications for up to 3 years of support to develop and test interventions to reduce the impact of HIV-associated stigma on the prevention and treatment of HIV infection and/or AIDS, and on the quality of life of People Living with HIV and/or AIDS (PLWH). The FOA will also support interventions to address the multiple intersecting stigmas and measurement of the stigmas at individual levels. Specifically, this initiative will support intervention research on a) novel stigma reduction strategies that link to increase in care-seeking behavior and/or decrease in transmission, b) reducing the impact of stigma on adolescent and/or youth health, c) strategies to cope with the complex burden of stigmatization due to HIV and one or more comorbidities/coinfections, d) reducing the effects of stigma on, and/or by, family members or care givers of PLWH and e) development of innovative and improved stigma measurement in the context of implementation of a stigma-reduction intervention. The overall goals are to understand how to reduce stigma as a factor in HIV transmission, to eliminate or mitigate the aspects of stigma that limit beneficial health outcomes for the infected and at-risk individuals and communities, and to conduct exploratory studies to determine the feasibility of stigma-reduction interventions related to HIV prevention, treatment and/or care in Low and Middle-Income Countries (LMICs).
Due December 20, 2021 and December 20, 2022. Med-RA deadline to receive draft documents for December 2021 due date: December 7.

Systems Biology for Infectious Diseases (U19 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-21-065.html>
The purpose of the Funding Opportunity Announcement (FOA) is to support research that employs systems biology approaches to human pathogens. The approach will generate and integrate large datasets into models that guide in vitro, in vivo and clinical studies, with the goals of predicting disease severity, predicting responses to vaccines and therapeutics, and identifying candidate targets for interventions.
Due January 14, 2022. Med-RA deadline to receive draft documents: January 3.

Virtual Consortium for Translational/Transdisciplinary Environmental Research (ViCTER) (R01 Clinical Trial Optional)<https://grants.nih.gov/grants/guide/rfa-files/RFA-ES-21-007.html>
The purpose of the ViCTER program is to use the R01 mechanism to foster and promote early-stage transdisciplinary collaborations and/or translational research efforts to address fundamental research among basic (technology and mechanism oriented), clinical (patient-oriented) and population-based researchers in the environmental health field. The newly established collaborative teams will come together in common interest to investigate potential linkages between human health and one or more environmental stressor(s). The ViCTER program is intended to support innovative high-risk, high-reward transdisciplinary/translational research projects that are more difficult to achieve in a typical R01 application. Collaboration among investigators at different institutions through a virtual consortium arrangement is encouraged.
Due February 1, 2022; February 1, 2023; and February 1, 2024. Med-RA deadline to receive draft documents for February 2022 due date: January 19.

Role of Astrocytes in Degeneration of the Neurovascular Unit in AD/ADRDs (R01 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/pa-files/PAR-22-037.html>
This funding opportunity announcement (FOA) invites basic disease-related research to address a gap in the basic research on the mechanisms of reactive astrogliosis in degeneration of the neurovascular unit that contributes to cognitive impairment and dementia. The neurovascular unit involves multiple pathways that contribute to neurodegeneration. Astrocytes, due to their overlapping roles regulating the blood brain barrier, neuronal health and response to degenerating cells, are uniquely positioned to be therapeutic targets for the AD/ADRDs.
Due February 4, 2022. Med-RA deadline to receive draft documents: January 24.

Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R21 / R01) Clinical Trial Not Allowed)
R21<https://grants.nih.gov/grants/guide/pa-files/PAR-22-038.html>
R01<https://grants.nih.gov/grants/guide/pa-files/PAR-22-039.html>
The purpose of these funding opportunity announcements (FOAs) is to encourage applications seeking to develop the next generation of brain stimulation devices for treating mental health disorders. Applications are sought that will either 1) develop novel brain stimulation devices or 2) significantly enhance, by means of hardware/software improvements, the effectiveness of brain stimulation devices that are currently U.S. Food and Drug Administration (FDA)-approved or cleared. Novel devices should move beyond existing electrical/magnetic stimulation and develop new stimulation techniques capable of increased spatiotemporal precision as well as multi-focal, closed-loop approaches. Applications seeking to develop new capabilities should focus on significant enhancement of the spatial resolution, depth of delivery, and/or precision of the device. Incremental changes to existing devices (e.g., software updates) are not within the scope of this announcement. Applications should be submitted by multi-disciplinary teams with diverse expertise including systems neuroscience, engineering, clinical, and regulatory affairs. Applications submitted in response to these FOAs should promote the development or significant enhancement of novel tools (hardware/software) for brain stimulation in humans. Although the application should focus on the engineering development and bench top testing of the tool, animals and limited human testing necessary to demonstrate initial proof of concept is allowable. Applications to these FOAs are not expected to be hypothesis-driven, but should propose design-directed, developmental, or discovery-driven technology research using integrative approaches. Applications that seek to study scientific or clinical hypotheses that simply utilize devices are outside the scope of this FOA.
Standard dates apply. Expires January 8, 2025. Med-RA deadline to receive draft documents for February 5, 2022 (R01) standard date: January 25; for February 16, 2022  (R21) standard date: February 3.

Pediatric Obesity Discovery Science Research to Improve Understanding of Risk and Causal Mechanisms for Obesity in Early Life (R01 Clinical Trial Optional)<https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-21-025.html>
The purpose of this Funding Opportunity Announcement (FOA) is to support innovative, discovery research studies to better characterize early-life risk factors and elucidate underlying causal mechanisms through which these risk factors contribute to the development of obesity during infancy and early childhood. Studies should aim to understand biological mechanisms that mediate behavioral and/or metabolic risk for obesity development in young children and how risk may be modified by other contributors such as psychosocial, contextual, and/or environmental factors. This FOA encourages multidisciplinary teams of scientists including, but not limited to those with expertise in basic, translational, clinical, and behavioral research.
Due March 8, 2022. Med-RA deadline to receive draft documents: February 23.

Clinical Relevance of the Linkage between Environmental Toxicant Exposures and Alzheimer’s Disease and Related Dementias (R01 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/pa-files/PAR-22-048.html>
This Funding Opportunity Announcement (FOA) supports mechanistic and early translational research focused on a more rigorous in-depth examination of the potential interactions of environmental toxins with genetic and non-genetic molecular targets known to influence Alzheimer’s Disease and Alzheimer’s Disease Related Dementias (AD/ADRD). It is expected that these studies will address the clinical relevance of these exposures on disease initiation, progression, or modification. Anticipated outcomes include an improved understanding of neurological mechanisms of chemical toxicities related to AD/ADRD, more evidence-based potential biomarkers of exposure and toxicity for those most at risk, as well as more data to support causality and potential approaches for mitigation. The scope of research includes mechanistic studies on the modification of known AD/ADRD targets by neurotoxins of concern, and conversely, whether known targets for these neurotoxins play a role in etiologies of AD/ADRD. The development and validation of neuropathological, neurophysiological and neurobehavioral animal models that simulate potential toxin exposures in humans is another example of supported studies. Preclinical studies of interactions of environmental toxicant with AD/ADRD in pilot human subject studies (that do not meet the NIH definition of clinical trial<https://grants.nih.gov/policy/clinical-trials/definition.htm>) are appropriate for this FOA. Interdisciplinary collaboration is required to address the various fields of study related to this research, e.g., neuroscience, aging, and environmental health sciences.
Due March 11, 2022. Med-RA deadline to receive draft documents: February 28.

Exploratory Grants in Cancer Control (R21 Clinical Trial Optional)<https://grants.nih.gov/grants/guide/pa-files/PAR-21-341.html>
Through this funding opportunity announcement, the National Cancer Institute encourages the submission of exploratory/developmental research grant applications that focus on different aspects of cancer control by modifying behavior, screening, and understanding etiologic factors contributing to the development of cancer, and developing ways to control cancer. The overarching goal is to provide support to promote the early and conceptual stages of research efforts on novel scientific ideas that have the potential to substantially advance population-based cancer research, such as the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (e.g. epidemiologic, biomedical, behavioral, health care delivery or clinical).
Due June 7, 2022; October 7, 2022; June 7, 2023; October 9, 2023; June 7, 2024; and October 8, 2024. Med-RA deadline to receive draft documents for June 2022 due date: May 24 (due to Memorial Day holiday).

Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery
R01 Clinical Trial Required<https://grants.nih.gov/grants/guide/pa-files/PAR-21-352.html>
This funding opportunity announcement (FOA) invites research projects that seek to explain the underlying mechanisms, processes, and trajectories of social relationships and how these factors affect outcomes in human health, illness, recovery, and overall wellbeing. Types of projects submitted under this FOA include mechanistic studies that are classified as clinical trials. Clinical trials that propose to influence a clinical outcome, test safety or feasibility of an intervention, demonstrate the clinical efficacy or effectiveness of an intervention, or analyze the effect size of an intervention on clinical outcomes are ineligible for this FOA. Types of studies that should submit under this FOA include clinical trials that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind.
R01 Basic Experimental Studies with Humans Required<https://grants.nih.gov/grants/guide/pa-files/PAR-21-349.html>
This funding opportunity announcement invites research projects that seek to explain the underlying mechanisms, processes, and trajectories of social relationships and how these factors affect outcomes in human health, illness, recovery, and overall wellbeing. Types of projects submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical and/or behavioral outcomes in humans to understand fundamental aspects of phenomena related to social connectedness and isolation. NIH considers such studies as Basic Experimental Studies with Humans that are prospective basic science studies involving human participants that meet the NIH definition of basic research and fall within the NIH definition of clinical trials. Applications should not propose a goal of clinical outcomes or products.
R01 Clinical Trials Not Allowed<https://grants.nih.gov/grants/guide/pa-files/PAR-21-350.html>
This funding opportunity announcement (FOA) invites research projects that seek to model the underlying mechanisms, processes, and trajectories of social relationships and how these factors affect outcomes in health, illness, recovery, and overall wellbeing. Both animal model and human subjects research projects are welcome; however, clinical trials are not allowed.
Due June 21, 2022; June 21, 2023; and June 21, 2024. Med-RA deadline to receive draft documents for June 2022 due date: June 8.

Pilot Practice-based Research for Primary Care Suicide Prevention (R34 Clinical Trial Optional)<https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-22-120.html>
This Funding Opportunity Announcement (FOA) encourages primary care practice-based research focused on rigorous evaluations of factors that impact or account for the effectiveness of existing suicide prevention practices and/or pilot clinical trials aimed at optimizing and pilot testing patient-, provider-, or systems-level suicide prevention strategies. Applications of interest include those that refine and test scalable strategies for use in primary care across different intercepts in the chain-of-care, including strategies for identifying individuals at risk, assessing and stratifying risk, providing brief interventions, promoting initial and ongoing engagement in indicated services, continued outcome monitoring and follow-up, and tracking patient outcomes. For purposes of this FOA, primary care is defined as pediatric practice, family practice, obstetrics/gynecology, internal medicine, and geriatric practice. Primary care practices range in size, resources and patient health needs; proposed strategies should meet the practice needs to be feasible, scalable, sustainable, and practice-ready. NIMH encourages prevention approaches that incorporate the use of mHealth (the use of mobile and wireless devices [cell phones, tablets, etc.]) and other design features that can facilitate scalability and sustainability, and deployment-focused research approaches that take into account the perspectives of key stakeholders (e.g., patients, providers, administrators) and system-level factors such as setting resources, workforce capacity, and training needs. This FOA also encourages studies that examine suicide prevention strategies that have broad reach, including potential for addressing risk among individuals who experience mental health service disparities (e.g., racial/ethnic minority groups; sexual and gender minorities, individuals living in rural areas, socioeconomically disadvantaged persons), and studies that explore how the proposed strategies can reduce health disparities and promote health equity.
Due June 21, 2022. Med-RA deadline to receive draft documents for June 2022 due date: June 8.

Sanofi US Educational Grants<https://sgrants.envisionpharma.com/vt_sgrants/>
Sanofi US is committed to funding high quality educational activities and materials in the therapeutic areas of interest to the company that have the potential to improve patient care and health outcomes. Sanofi US is currently accepting educational grant applications in the following therapeutic area(s):

  *   US Cardiovascular, specific to the Area of Interest:
     *   The role of AADs in Early Rhythm Control and the Management of Atrial Fibrillation
  *   US Multiple Sclerosis
  *   US and Global Oncology, specific to the Area of Interest:
     *   Breast Cancer
  *   US Oncology, specific to the following Areas of Interest:
     *   Prostate Cancer
     *   Tumor Lysis
     *   HSCT: stem cell mobilization and collection during autologous HSCT
  *   US and Global Rare Blood Disorder, specific to the Areas of Interest:
     *   Hemophilia
     *   Cold Agglutinin Disease (CAD)
     *   Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
     *   Immune Thrombocytopenia (ITP)
  *   US and Global Rare Genetic Diseases, specific to the Areas of Interest:
     *   Acid sphingomyelinase deficiency (ASMD)
     *   Fabry Disease
     *   Gaucher Disease
     *   Pompe Disease
     *   MPS1
     *   Lysosomal Storage Disorders
     *   Other Genetic Disorders
  *   US Transplantation, specific to the Area of Interest:
     *   Immunosuppressive Strategies to Reduce Transplant Rejection
The Sanofi-Regeneron Alliance is currently accepting educational grant submissions in the following therapeutic area(s):

  *   US and Global Immunology, specific to the following Area(s) of Interest:
     *   Atopic Dermatitis
     *   Chronic Spontaneous Urticaria (CSU)
     *   Prurigo Nodularis (PN)
  *   US and Global Immunology/Respiratory, specific to the following Area of Interests, will be managed by Regeneron
     *   Asthma
     *   Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
     *   Eosinophilic Esophagitis (EoE)
Due at least 12-16 weeks in advance of request for notification date. Med-RA deadline to receive draft documents: 10 business days before submission to sponsor.

To search for additional funding opportunities, please visit CoM’s unofficial funding opportunities blog<https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e=>.
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://lists.fsu.edu/pipermail/com_funding_opportunities/attachments/20211015/b7875245/attachment.html>